<DOC>
	<DOCNO>NCT01076803</DOCNO>
	<brief_summary>The primary objective study assess efficacy Lanreotide 120 mg relief clinical symptom due malignant bowel obstruction inoperable patient . This effect evaluate percentage responder patient 7 14 day one administration lanreotide 120 mg. ( A responder patient define either patient experience &lt; or= 1 vomit episode per day least three consecutive day patient NGT remove without vomit recurrence least three consecutive day ) The total number visit depend clinical situation , 5 visit obligatory : Day ( D ) -3/-0 , Day 1 , Day 7 , Day 14 , Day 28 Inclusion visit ( D-3/-0 ) : eligibility , PIC , obstruction history , clinical exam , vital sign , diary card , VAS scale , cc medication , blood sample Visit D1 : injection Visit D7/D14/28 : clinical exam , nutrition procedure , result biochemical analyse , adverse event , cc medication In visit , patient keep fill diary VAS scale</brief_summary>
	<brief_title>Efficacy Safety Lanreotide 120 Milligram ( mg ) Palliative Treatment Clinical Symptoms Associated With Malignant Intestinal Obstruction Inoperable Patients</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>PIC &gt; = 18 year time enrolment Diagnosis digestive obstruction malignant origin Diagnosis peritoneal carcinomatosis confirm ct scan within previous 3 month Inoperability decide surgical consultation Operable obstruction Bowel obstruction explain non malignant cause Signs bowel obstruction Prior treatment somatostatin analogue within previous 60 day Known hypersensitivity test material relate compound Previous enrolment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Malignant intestinal obstruction inoperable patient</keyword>
</DOC>